Study Summary
Following pre-treatment with cyclophosphamide and/or fludarabine, NY-ESO-1-specific TCR gene transduced T lymphocytes are transferred to the patients with NY-ESO-1-expressing solid tumors.
Want to learn more about this trial?
Request More InfoInterventions
TBI-1301DRUG
TBI-1301(5\*10\^8 or 5\*10\^9) is administered.
CyclophosphamideDRUG
Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
FludarabineDRUG
Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Mie University Hospital | Tsu | Mie-ken | Japan |